AdipoGen Life Sciences

DYRK1A/B Inhibitor AnnH75

CHF 180.00
In stock
AG-CR1-3651-C500500 µgCHF 180.00
More Information
Product Details
Synonyms 2-(1-Chloro-7-methoxy-9H-pyrido[3,4-b]indol-9-yl)acetonitrile; AnnH75
Product Type Chemical


MW 271.7
Purity Chemicals ≥98% (HPLC, NMR)
Appearance Pale yellow solid.
Solubility Soluble in DMSO.
Identity Determined by 1H-NMR.
Other Product Data

DMSO Stock Solution: Prior to performing biological experiments the DMSO stock solution should be further diluted into water or other aqueous buffers to ensure that the residual amount of DMSO is insignificant, since DMSO may have physiological effects at high concentrations.

Smiles ClC1=NC=CC2=C1N(CC#N)C3=CC(OC)=CC=C32
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Potent selective membrane-permeable DYRK1A (IC50=181nM) and DYRK1B inhibitor. Off-target inhibition of CLK1, CLK4 and Haspin/GSG2.
  • Shows no inhibitory effects on monoamine oxidase A (MAO A).
  • Inhibited the cotranslational tyrosine autophosphorylation of DYRK1A and threonine phosphorylation of an exogenous substrate protein with similar potency.
  • Dose-dependently reduced the phosphorylation of three known DYRK1A substrates (SF3B1, SEPT4 and tau) without negative effects on cell viability in celular assays.
  • Moderate inhibitor of CDK8, CLK2, GRK4, MEK2, PIM1, PIM3 and PKCε.
  • Shows minimal cytotoxic effects in HeLa and PC12 cells up to 10µM.
  • The pleiotropic protein kinase DYRK1A has diverse functions in cell cycle control, neuronal differentiation and synaptic transmission and has attracted increasing interest as a potential drug target, due to its role in the pathology of Down syndrome, neurodegenerative diseases such as Alzheimer's disease and cancer. The closely related kinase DYRK1B has been associated with cancer cell survival by arresting cells in a quiescent state to allow cellular repair and mutations in DYRK1B might be causative in metabolic syndrome.
Product References
  1. Selectivity profiling and biological activity of novel beta-carbolines as potent and selective DYRK1 kinase inhibitors: K. Ruben, et al.; PLos One 10, e0132453 (2015)
  2. Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases: M.F. Lindberg, et al.; J. Med. Chem. ahead of print (2023)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.